Looney Ann-Marie, Ahearne Caroline, Boylan Geraldine B, Murray Deirdre M
Neonatal Brain Research Group, Department of Paediatrics and Child Health, Irish Centre for Fetal and Neonatal Translational Research, Cork University Maternity Hospital , Cork , Ireland.
Front Neurol. 2015 Dec 21;6:264. doi: 10.3389/fneur.2015.00264. eCollection 2015.
Brain-specific glial fibrillary acidic protein (GFAP) has been suggested as a potential biomarker for hypoxic ischemic encephalopathy (HIE) in newborns (1, 2). Previous studies have shown increased levels in post-natal blood samples. However, its ability to guide therapeutic intervention in HIE is unknown. Therapeutic hypothermia for HIE must be initiated within 6 h of birth, therefore a clinically useful marker of injury would have to be available immediately following delivery. The goal of our study was to examine the ability of GFAP to predict grade of encephalopathy and neurological outcome when measured in umbilical cord blood (UCB). Infants with suspected perinatal asphyxia (PA) and HIE were enrolled in a single, tertiary maternity hospital, where UCB was drawn, processed, and bio-banked at birth. Expression levels of GFAP were measured by ELISA. In total, 169 infants (83 controls, 56 PA, 30 HIE) were included in the study. GFAP levels were not increased in UCB of case infants (PA/HIE) when compared to healthy controls or when divided into specific grades of HIE. Additionally, no correlation was found between UCB levels of GFAP and outcome at 36 months.
脑特异性胶质纤维酸性蛋白（GFAP）已被认为是新生儿缺氧缺血性脑病（HIE）的一种潜在生物标志物（1,2）。先前的研究表明，产后血样中的GFAP水平会升高。然而，其在HIE中指导治疗干预的能力尚不清楚。HIE的治疗性低温必须在出生后6小时内开始，因此，一种临床上有用的损伤标志物必须在分娩后立即获得。我们研究的目的是检测在脐带血（UCB）中检测GFAP时，其预测脑病分级和神经学结局的能力。疑似围产期窒息（PA）和HIE的婴儿被纳入一家三级妇产医院的单一研究，在出生时采集UCB、进行处理并储存于生物样本库。通过酶联免疫吸附测定法（ELISA）测量GFAP的表达水平。该研究共纳入169名婴儿（83名对照、56名PA、30名HIE）。与健康对照相比，病例婴儿（PA/HIE）的UCB中GFAP水平未升高，将HIE分为特定等级时也是如此。此外，未发现UCB中GFAP水平与36个月时的结局之间存在相关性。
